Compare Costco Wholesale Corporation (COST) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Illumina, Inc. — how do they compare? Costco Wholesale Corporation trades at $945.95 (market cap $420.05B), while Illumina, Inc. trades at $265 (market cap $39.95B). The key difference: Costco Wholesale Corporation is far larger — about 10.5× Illumina, Inc.'s market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 132 Days and Illumina, Inc. for 83 Days on average.
| COST | ILMN | |
|---|---|---|
Market Cap | $420.05B | $39.95B |
Volume | 2,087,565 | 3,169,503 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $293.69 |
52-Week Low | $849.63 | $91.00 |
Typical Hold Time | 132 Days | 83 Days |
Enterprise Value | $407.33B | $41.31B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco Wholesale Corporation (COST) trades at $942.25, up 0.7% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong March 2026 sales growth of 11.3% year-over-year, and fiscal 2025 revenue reached $275.24 billion with net income of $8.10 billion. Analyst consensus is strongly bullish with a $1,090 price target, though valuation ratios like P/E of 45.39 are elevated.
The outlook remains positive due to membership fee growth and expansion, but risks include high valuation sensitivity and competitive pressures. Earnings momentum is solid with recent beats, supporting the buy-rated sentiment, yet any market pullback could present a better entry point for long-term investors.
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
